ArticleJournal of molecular neuroscience : MN2026
LDHA as a Potential Therapeutic Target for Lactylation Regulation in Spinal Cord Injury: Integrated Bioinformatics Analysis, Experimental Validation, and Drug Prediction.
Article in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lactate metabolism and its epigenetic modification, lactylation, are emerging regulators in neurological disorders, yet their roles in spinal cord injury (SCI) remain unclear. Here, we mined SCI transcriptomes from GEO and identified 13 differentially expressed lactylation-related genes (DE-LRGs), with lactate dehydrogenase A (LDHA) significantly upregulated. Immune-infiltration analysis linked LDHA to T cells gamma delta, and Mfuzz time-series clustering showed dynamic LDHA upregulation during acute SCI, which was validated in GSE45006. Random forest and ROC analyses supported the diagnostic value of LDHA. PPI and GeneMANIA networks positioned LDHA at the intersection of lactate metabolism and immune regulation. Drug prediction with Enrichr/DSigDB and docking highlighted folic acid and quercetin dihydrate as candidate compounds. GSVA/GSEA indicated LDHA enrichment in immune activation, metabolic regulation, and stress-response pathways. Immunofluorescence in a rat SCI model confirmed sustained LDHA elevation from 1 to 3 days around the lesion. Importantly, Western blot validation (3 days post-injury) demonstrated increased nuclear HIF-1α and p-STAT3^Y705 (total STAT3 unchanged) together with elevated CXCL1, IL-6, and CCL2 and the infiltration marker MPO/CD68; these changes were attenuated by LDHA inhibition (FX11) and partially rescued by exogenous lactate, supporting an LDHA → lactate → HIF-1α/STAT3 → chemokine/infiltration axis in acute SCI. Collectively, our data identify LDHA as a key lactylation-related regulator in SCI that contributes to pathogenesis via metabolic reprogramming and immune modulation, highlighting its promise as a diagnostic biomarker and therapeutic target.
Indexed as
Identifiers
41483356What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.